{"id":"W2043068439","doi":"10.1016/j.urology.2008.08.138","title":"POD-3.07: An Open-Label, Phase II Trial of 250mg Gefitinib (Iressa) in Prostate Cancer Patients with Early Biochemical Failure Post-prostatectomy","year":2008,"lang":"en","type":"article","venue":"Urology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); University of British Columbia; Western University; University of Toronto","funders":"","keywords":"Medicine; Gefitinib; Prostate cancer; Prostatectomy; Urology; Internal medicine; Discontinuation; Oncology; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001297962,0.001956973,0.003006916,0.0005302585,0.0005401071,0.001472486,0.001193878,0.001615976,0.006154429],"category_scores_gemma":[0.0008741969,0.0007506026,0.002427889,0.0004524127,0.001572152,0.001354186,0.0003968047,0.00523269,0.00148796],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001208252,"about_ca_system_score_gemma":0.002187995,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002181022,"about_ca_topic_score_gemma":0.007117003,"domain_scores_codex":[0.9996427,0.0001299036,0.00001340256,0.00006070735,0.00002819325,0.0001250736],"domain_scores_gemma":[0.9995387,0.00007663333,0.00007490961,0.00003374827,0.00001914664,0.0002568218],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8163491,0.03970562,0.003902769,0.0009528758,0.002198603,0.0002214067,0.0002074158,0.003383571,0.01617399,0.0005133193,0.01073591,0.1056554],"study_design_scores_gemma":[0.8998092,0.0907663,0.00490226,0.00002251579,0.0003811597,0.0001803485,0.00004004215,0.0013924,0.001089551,0.0002210068,0.001158533,0.00003663851],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873979,0.002806835,0.0007293301,0.001370477,0.000340795,0.001570894,0.002129398,0.0006560312,0.002998388],"genre_scores_gemma":[0.9868404,0.002160964,0.001853005,0.001509988,0.0002453538,0.001374904,0.002966423,0.00007886031,0.002970102],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006154429,"threshold_uncertainty_score":0.02058858,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02351812071423492,"score_gpt":0.3063591483364527,"score_spread":0.2828410276222177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}